Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways
- Rabindra Tirouvanziam*,†,‡,
- Yael Gernez*,
- Carol K. Conrad*,
- Richard B. Moss*,
- Iris Schrijver§,
- Colleen E. Dunn*,
- Zoe A. Davies*,
- Leonore A. Herzenberg†, and
- Leonard A. Herzenberg†
- Departments of *Pediatrics,
- †Genetics, and
- §Pathology, Stanford University School of Medicine, Stanford, CA 94305
-
Contributed by Leonard A. Herzenberg, December 31, 2007 (received for review December 20, 2007)
Abstract
Blood neutrophils recruited to cystic fibrosis (CF) airways are believed to be rapidly killed by resident bacteria and to passively release elastase and other toxic by-products that promote disease progression. By single-cell analysis, we demonstrate that profound functional and signaling changes readily occur within viable neutrophils recruited to CF airways, compared with their blood counterparts. Airway neutrophils have undergone conventional activation, as shown by decreased intracellular glutathione, increased lipid raft assembly, surface mobilization of CD11b+ and CD66b+ granules, and increased levels of the cytoskeleton-associated phospho-Syk kinase. Unexpectedly, they also mobilize to the surface CD63+ elastase-rich granules, usually confined intracellularly, and lose surface expression of CD16 and CD14, both key receptors in phagocytosis. Furthermore, they express CD80, major histocompatibility complex type II, and the prostaglandin D2 receptor CD294, all normally associated with other lineages, which reflects functional reprogramming. This notion is reinforced by their decreased total phosphotyrosine levels, mirroring a postactivated stage, and increased levels of the phospho-S6 ribosomal protein, a key anabolic switch. Thus, we identified a subset of neutrophils within CF airways with a viable but dysfunctional phenotype. This subset provides a possible therapeutic target and indicates a need to revisit current paradigms of CF airway disease.
Footnotes
- ‡To whom correspondence should be addressed at: Beckman Center B013, Stanford University School of Medicine, Stanford, CA 94305-5318. E-mail: tirouvan{at}stanford.edu
-
Author contributions: R.T., R.B.M., Leonore A. Herzenberg, and Leonard A. Herzenberg designed research; R.T., Y.G., C.K.C., I.S., C.E.D., and Z.A.D. performed research; R.T. contributed new reagents/analytic tools; R.T. and Y.G. analyzed data; and R.T., C.K.C., and R.B.M. wrote the paper.
-
The authors declare no conflict of interest.
-
This article contains supporting information online at www.pnas.org/cgi/content/full/0712386105/DC1.
- © 2008 by The National Academy of Sciences of the USA





